The U.S. Food and Drug Administration has granted rare pediatric disease and orphan drug designations to for OXU-003 (Oxular Limited) for the treatment of retinoblastoma.

In preclinical models, the anti-tumor drug has been shown to be effective as a stand-alone therapy, as well as complementary to other current treatments.

“I am very pleased to see the FDA’s acknowledgement of the critical and urgent need to develop an effective, safer and easily accessible treatment for retinoblastoma which is such a devastating disease,” said Manoj Parulekar, Paediatric Consultant…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Sep 15, 2020

Patients with familial exudative vitreoretinopathy need life-long screening for retinal detachment

Screening for all patients with familial exudative vitreoretinopathy (FEVR) should continue throughout life due to the long-term risk of progression to retinal detachment, even in those previously treated with peripheral laser, according to a study.

In this retrospective consecutive case…

Journal Scan

  1. Sep 14, 2020

Vitamin D Deficiency Worsens Symptoms of Dry Eye Disease

In this systematic review and meta-analysis, 10 clinical studies were identified that evaluated the association between vitamin D levels and dry eye. Mean serum vitamin D levels were found to be 3.99 ng/ml lower in patients with dry eye than in control patients.

In patients with vitamin…